Table 1. Patient details.
| Patient number | Sex | Age (years) | Diagnosis | Course studied | Course type | Ifosfamide dose (g m−2) | Other medication |
|---|---|---|---|---|---|---|---|
| 1 | M | 2 | RM | 3 | IE1 | 9 | Imi, ond, tei |
| 2 | F | 3 | RM | 4 | IE1 | 9 | acy, cot, flu, fru, ond |
| 3 | M | 10 | HE | 1 | IE1 | 9 | Cot, ond, par |
| 4 | M | 17 | RM | 1 | IE1 | 9 | Chl, dex, gav, fru, ond, par, sen, tem |
| 5 | M | 5 | RM | 5 | IVA1 | 9 | Cep, chh, dex, lac, tri |
| 6 | F | 2 | RM | 3 | IVA1 | 9 | Chh, dex, ond, tri |
| 7 | M | 19 | MFH | 1 | IE1 | 9 | Dih, flu, fru, imi, lac, nab, ond |
| 8 | F | 15 | ES | 4 | IVA3 | 6 | Dex, flu, lac, mor, nab, ond, ran |
| 9 | M | 4 | RM | 2 | IVA1 | 9 | Dex, ond |
| 10 | M | 19 | PNT | 4 | IE1 | 9 | Ami, cod, cyc, dex, flu, gav, imi, met, ran, sen, sep, tei, tem |
| 11 | M | 6 | RM | 4 | IVA2 | 6 | Cep, fru, ond, lor, mtp, ond |
| 12 | F | 3 | RM | 3, 6 | IVE | 9 | Dex, ond |
| 13 | M | 19 | RM | 5, 9 | IVE | 9 | Ami, car, cod, dex, met, ond mbl cla |
| 14 | M | 19 | OS | 2, 3 | IE2 | 9 | Dex, lac, met, ond |
| 15 | M | 15 | OS | 2, 4 | IE2 | 9 | Dex, met, ond |
| 16 | M | 19 | ES | 3, 5 | IVAd | 6 | Cyc, dex, met, ond |
| 17 | M | 7 | RM | 2, 4 | IVA2 | 6 | Car, cod, cyc, lac, ond |
| 18 | M | 10 | ES | 2, 4 | IVA3 | 6 | Dex, ond, cyc, dex, lor, met |
| 19 | F | 3 | RM | 3, 4 | IVA2 | 6 | Dex, met, ond, ran, par |
Diagnosis: ES=Ewings sarcoma; HE=haemangioendothelioma; MFH=malignant fibrous histiocytoma; PNT=primitive neuroectodermal tumour; OS=osteogenic sarcoma; RM=rhabdomyosarcoma.
Course type: IE1 – ifosfamide 3 g m−2 day−1 continuous infusion over 3 days. Etoposide 200 mg m−2 day−1 as a 2 h infusion on 3 consecutive days. IE2 – as IE1, etoposide 150 mg m−2 day−1. IVA1 – ifosfamide 3g m−2 day−1 as a 3 h infusion on 3 consecutive days. Actinomycin D and vincristine both 1.5 mg m−2 bolus on day 1 only. IVA2 – as IVA1, ifosfamide on 2 days only. IVA3 – as IVA1, ifosfamide 2g m−2 day−1 1 h infusion on 3 consecutive days. IVAd – as IVA3, but adriamycin 20 mg m−2 day−1 as a 6 h infusion on 3 consecutive days, no actinomycin D. IVE – ifosfamide 3g m−2 day−1 as a 3 h infusion, etoposide 150 mg m−2 as a 4 h infusion, each on 3 consecutive days. Vincristine 1.5 mg m−2 bolus on day 1 only.
Other medication (drugs taken during study): Acy=acyclovir; amy=amitriptyline; car=carbamazepine; cep=cephalexin; chh=chloral hydrate; chl=chlorpromazine; cla=clarithromycin; cod=codeine phosphate; cot=cotrimoxazole; cyc=cyclozine; dex=dexamethasone; dih=dihydrocodeine; dox=doxorubicin; flu=fluconazole; fru=frusemide; gav=gaviscon; imi=imipenem; lac=lactulose; lar=lorazepam; mbl=methlyene blue; met=metoclopropamide; mtp=methotrimeprazine; mor=morphine sulphate; nab=nabilone; ond=ondansetron; par=paracetamol; ran=ranitidine; sen=senna; tei=teicoplanin; tem=temazepam; tri=trimeprazine. Drugs thought to inhibit CYP3A4 are shown in bold, drugs known to induce CYP3A4 are underlined. All patients were also hydrated with mesna at an equivalent dose to ifosfamide (2 or 3 g m−2 day−1 in 3 l). This was administered as a continuous infusion throughout the course and for 12 h after completion of the course.